

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

Project Data Sphere

RRID:SCR_003726

Type: Tool

Proper Citation

Project Data Sphere (RRID:SCR_003726)

Resource Information

URL: <https://www.projectdatasphere.org/>

Proper Citation: Project Data Sphere (RRID:SCR_003726)

Description: Initiative to advance oncology research by enabling collaborative sharing of historical oncology clinical trial data through a universal platform (database). The initiative aims to network all stakeholders in the cancer community researchers, industry, academia, advocacy, and other organizations to share insights and collaborate on issues that could not be solved individually. To do this, they have made efforts to address issues of data privacy, security, intellectual property, resources, and incentives as part of its effort to maximize participation. Data contributions include control arms of clinical trials, and the platform uses data-security precautions and analytics to pool multiple studies associated with the same diagnosis in a manner that seeks to protect the privacy of patients and the security of the data contributed.

Abbreviations: PDS

Synonyms: DataSphere, Project Data Sphere Initiative, Project DataSphere, Project Data Sphere LLC

Resource Type: consortium, data or information resource, database, organization portal, portal

Defining Citation: [PMID:25876994](#)

Keywords: drug, oncology, clinical trial, data sharing, consortium, phase iii

Resource Name: Project Data Sphere

Resource ID: SCR_003726

Alternate IDs: nlx_157911, DOI:10.34949, DOI:10.17616/R31NJMJB, r3d100010760

Alternate URLs: <https://doi.org/10.17616/R36H16>, <https://doi.org/10.17616/r31NJMJB>, <https://doi.org/10.34949/>, <https://dx.doi.org/10.34949/>, <https://doi.org/10.17616/R3KP67>

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260919T195024+0000

Ratings and Alerts

No rating or validation information has been found for Project Data Sphere.

No alerts have been found for Project Data Sphere.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Stull DE, et al. (2026) Causal Cascade of Symptoms on Patient Functioning and Health-Related Quality of Life in Non-Small Cell Lung Cancer and Metastatic Breast Cancer. JCO clinical cancer informatics, 10, e2500127.

Zhu J, et al. (2026) Confidence intervals and point estimates for treatment effects in adaptive enrichment designs. Statistical methods in medical research, 35(4), 827.

Ren S, et al. (2025) Quantitative bias analysis for unmeasured confounding in unanchored population-adjusted indirect comparisons. Research synthesis methods, 16(3), 509.

Ian D, et al. (2025) A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm. medRxiv : the preprint server for health sciences.

Struebing A, et al. (2024) Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer. Journal of comparative effectiveness research, 13(5), e230175.

Juwara L, et al. (2024) An evaluation of synthetic data augmentation for mitigating covariate bias in health data. Patterns (New York, N.Y.), 5(4), 100946.

El Emam K, et al. (2024) An evaluation of the replicability of analyses using synthetic health data. Scientific reports, 14(1), 6978.

Rippin G, et al. (2024) Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. Drug safety, 47(12), 1245.

- Lin CW, et al. (2024) A multistate platform model for time-to-event endpoints in oncology clinical trials. *CPT: pharmacometrics & systems pharmacology*, 13(1), 154.
- Zhou J, et al. (2023) Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. *Nature communications*, 14(1), 417.
- Chen H, et al. (2023) Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials. *Breast (Edinburgh, Scotland)*, 71, 1.
- Halkola AS, et al. (2023) OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. *PLoS computational biology*, 19(3), e1010333.
- Bakoyannis G, et al. (2023) Estimating optimal individualized treatment rules with multistate processes. *Biometrics*, 79(4), 2830.
- Caldeira D, et al. (2023) Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort. *Journal of endocrinological investigation*, 46(7), 1423.
- Zhudenkov K, et al. (2022) A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics. *CPT: pharmacometrics & systems pharmacology*, 11(4), 425.
- Bartoš F, et al. (2022) Informed Bayesian survival analysis. *BMC medical research methodology*, 22(1), 238.
- Abuhelwa AY, et al. (2022) A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma. *Cancer chemotherapy and pharmacology*, 89(4), 479.
- Emam KE, et al. (2021) Optimizing the synthesis of clinical trial data using sequential trees. *Journal of the American Medical Informatics Association : JAMIA*, 28(1), 3.
- Jiang S, et al. (2021) Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. *BMC cancer*, 21(1), 1308.
- Zeng R, et al. (2021) PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients. *Frontiers in immunology*, 12, 724443.